LIBTAYO(Lebrikizumab)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
LIBTAYO (cemiplimab-rwlc) is a monoclonal antibody that works as a programmed cell death protein-1 (PD-1) inhibitor. It is primarily used for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or radiation. By blocking the PD-1 receptor, LIBTAYO enhances the immune system’s ability to target and destroy cancer cells, offering an important treatment option for advanced cases of CSCC.
The recommended dosage of LIBTAYO is 350 mg administered intravenously every 3 weeks. It can be continued until disease progression or intolerable side effects occur. While effective, LIBTAYO may cause immune-mediated reactions, infusion-related reactions, and fetal harm, which necessitate careful monitoring during treatment.
Generic name
LIBTAYO(Lebrikizumab)
English name
Lebrikizumab
Alternative Names
LIBTAYO
Indications
LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or radiation.
Therapeutic Target
LIBTAYO targets the programmed cell death protein-1 (PD-1) receptor.
Active Ingredients
Cemiplimab-rwlc, a monoclonal antibody that targets and inhibits PD-1, blocking its interaction with PD-L1 and PD-L2, thereby potentiating immune system activity against tumors.
specifications
350mg/7mL/box
Description
LIBTAYO is a programmed cell death protein-1 (PD-1) inhibitor, a monoclonal antibody designed to block the PD-1 receptor. By inhibiting this receptor, it restores the ability of the immune system to detect and destroy cancer cells. It is specifically approved for use in patients with advanced cutaneous squamous cell carcinoma (CSCC) who are not amenable to curative surgery or radiation. LIBTAYO has been shown to provide significant clinical benefit, including prolonged progression-free survival, in these patients.
Dosage and Administration
Recommended Dosage:The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks. Treatment should continue until disease progression or the development of unacceptable toxicity;
Infusion Time: 30 minutes;
Frequency: Every 3 weeks.
Contact Us
Mailbox:Info@Lucius.La
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved
